2. Chevkin C., James I. F. and Goldstein A. (1982) Dynorphin is a specific endogenous ligand of Ŕ-opioid receptor.
Science 215, 413–415.
3. Corbett A. D., Paterson S. J., McKnight A. T., Magnan J. and Kosterlitz H. W. (1982) Dynorphin (1–8) and
dynorphin (1–9) are ligands for kappa subtypes of opiates receptors. Nature 299, 79–81.
4. D'Amour F. E. and Smith D. L. (1941) A method for determining loss of pain sensation. J. Pharmac. exp. Ther. 72,
74–79.
5. Haley T. J. and McCormick W. G. (1957) Pharmacological eVects produced by intracerebral injections of drugs in the
conscious mouse. Br. J. Pharmac. 12, 12–15.
6. Ho ̈ llt V., Przewlocki R. and Herz A. (1978) Radioimmunoassay of â-endorphin basal and stimulated levels in
extracted rat plasma. Naunyn-Schiedeberg's Arch. Pharmac. 303, 171–174.
7. Hylden J. L. K. and Wilcox G. L. (1980) Intrathecal morphine in mice: a new technique. Eur. J. Pharmac. 67,
313–316.
8. Knapp R. I., Vaughn L. K. and Yamamura H. I. (1995) Selective ligands for μ and ä opioid receptors. In The
Pharmacology of Opioid Peptides (ed. L. F. Tseng), pp. 1–27. Harwood Academic Publishers, Chur, Switzerland.
9. Magnan J., Peterson S. J., Tavani A. and Kosterlitz H. W. (1982) The binding spectrum of narcotic analgesic drugs
with diVerent agonist and antagonist properties. Naunyn-Schmiedeberg's Arch. Pharmac. 319, 197–205.
10. Nock B. (1995) Ŕ and å opioid receptor binding. In The Pharmacology of Opioid Peptides (ed. L. F. Tseng), pp. 29–56.
Harwood Academic Publishers, Chur, Switzerland.
11. Nock B., Giordano A. L., Cicero T. J. and O'Connor L. H. (1990) AYnity of drugs and peptides for U-69,593sensitive and-insensitive kappa-opioid binding sites: the U-69,593-insensitive sites appear to be the â-endorphinspecific epsilon receptor. J. Pharmac. exp. Ther. 254, 412–419.
12. Perry D. C., Rosenbaum J. S., Kurowski M. and Sadee W. (1982) [3H]Etorphine receptor binding in vivo. Small
fractional occupancy elicits analgesia. Molec. Pharmac. 21, 272–279.
13. Richards M. L. and Sadee W. (1985) In vivo opiate receptor binding of oripavine to μ, ä, and Ŕ sites in rat brain as
determined by an ex vivo labeling method. Eur. J. Pharmac. 114, 343–353.
14. Rosenbaum J., Holford N. H. G., Richards M. L., Aman R. A. and Sadee W. (1983) Discrimination of three types of
opioid binding sites in rat brain in vivo. Molec. Pharmac. 25, 242–248.
15. Stevens C. and Yaksh T. (1986) Dynorphin A and related peptides administered intrathecally in the rats: search for
putative kappa opiate receptor activity. J. Pharmac. exp. Ther. 238, 833–838.
16. Suh H. H., Fujimoto J. M. and Tseng L. F. (1989) DiVerential mechanisms mediating â-endorphin- and
morphine-induced analgesia in mice. Eur. J. Pharmac. 168, 61–70.
17. Suh H. H. and Tseng L. F. (1988) Intrathecal â-funaltrexamine antagonizes intracerebroventricular â-endorphin- but
not morphine-induced analgesia in mice. J. Pharmac. exp. Ther. 245, 587–593.
18. Suh H. H. and Tseng L. F. (1990) Delta- but not mu-opioid receptors in the spinal cord are involved in antinociception
induced by â-endorphin given intracerebroventricularly in mice. J. Pharmac. exp. Ther. 253, 981–986.
19. Suh H. H. and Tseng L. F. (1990) DiVerent types of opioid receptors mediating analgesia induced by morphine,
DAMGO, DPDPE, DADLE and â-endorphin in mice. Naunyn-Schmiedeberg's Arch. Pharmac. 342, 67–71.
20. Suh H. H., Tseng L. F. and Li C. H. (1988) â-Endorphin-(1–27) antagonizes â-endorphin- but not morphine-,
d-Pen2-d-Pen5-enkephalin- and U50,488H-induced analgesia in mice. Neuropharmacology 27, 957–963.
21. Tseng L. F. (1995) Mechanisms of â-endorphin-induced antinociception. In The Pharmacology of Opioid Peptides (ed.
L. F. Tseng), pp. 249–269. Harwood Academic Publishers, Chur, Switzerland.
22. Tseng L. F. and Collins K. A. (1993) Spinal involvement of both dynorphin A and Met-enkephalin in the
antinociception induced by intracerebroventricularly-administered bremazocine but not morphine in the mouse.
J. Pharmac. exp. Ther. 266, 1430–1438.
23. Tseng L. F., Collins K. A. and Portoghese P. S. (1993) Spinal ä but not ä opioid receptors are involved in
21
intracerebroventricular â-endorphin-induced antinociception in the mouse. Life Sci. 52, PL211–PL215.
24. Tseng L. F. and Fujimoto J. M. (1984) Evidence that spinal endorphin mediates intraventricular â-endorphin-induced
tail-flick inhibition and catalepsy. Brain Res. 302, 231–237.
25. Tseng L. F. and Fujimoto J. M. (1985) DiVerential actions of intrathecal naloxone on blocking the tail-flick inhibition
induced by intraventricular â-endorphin and morphine in rats. J. Pharmac. exp. Ther. 232, 74–79.
26. Tseng L. F., Higgins M. J., Hong J.-S., Hudson P. M. and Fujimoto J. M. (1985) Release of immunoreactive
Met-enkephalin from the spinal cord by intraventricular â-endorphin but not morphine in anesthetized rats. Brain Res.
343, 60–69.
27. Tseng L. F., King R. C. and Fujimoto J. M. (1986) Release of immunoreactive Met-enkephalin by intraventricular
â-endorphin in anesthetized rats. Regul. Pept. 14, 181–192.
28. Tseng L. F. and Suh H. H. (1989) Intrathecal [Met5]enkephalin antibody blocks analgesia induced by intracerebroventricular â-endorphin but not morphine in mice. Eur. J. Pharmac. 173, 171–176.
29. Xu J. Y., Fujimoto J. M. and Tseng L. F. (1992) Involvement of supraspinal å and μ opioid receptors in the inhibition
of the tail-flick response induced by etorphine in the mouse. J. Pharmac. exp. Ther. 263, 246–252.
